The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule. The AHA expressed support for several policies in the rule, including direct supervision requirements for certain cardiac rehabilitation services and removing four measures from the Outpatient Quality Reporting program that were recently finalized for removal from the Inpatient Quality Reporting Program, along with the proposal to offer time extensions for data reporting for facilities experiencing an extraordinary circumstance. Provisions the AHA opposed include reducing payment for all drug administration services furnished in off-campus hospital provider-based departments to the “physician fee schedule-equivalent” rate of 40% of the OPPS payment amount, eliminating the inpatient-only list over three years, weakening the ASC Covered Procedures List standard criteria and general exclusion criteria and accelerating the timeline for clawing back funds from CMS' unlawful policy between CY 2018 and 2022 that harmed certain hospitals participating in the 340B Drug Pricing Program.

Related News Articles

Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The 5th U.S. Circuit Court of Appeals Feb. 9 affirmed a district court ruling upholding Louisiana’s 340B contract pharmacy law. The state law prohibits…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
The Coalition to Strengthen America’s Healthcare Feb. 5 released a new research brief examining the impact of proposed site-neutral payment policies on…
Headline
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…